Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 7/20 | 0.44 |
| ▸ | NOS2 | P35228 | 6/20 | 0.44 |
| ▸ | NOS3 | P29474 | 6/20 | 0.44 |
| ▸ | TACR1 | P25103 | 4/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.40 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10104415 | 0.90 | TACR1 (0.45) | NOS1NOS2NOS3TACR1 | |
| SCHEMBL14492896 | 0.89 | TACR1 (0.50) | NOS1NOS2NOS3TACR1TAAR1 | |
| SCHEMBL15077173 | 0.82 | TACR1 (0.46) | NOS1NOS2NOS3TACR1TAAR1 | |
| SCHEMBL10104524 | 0.81 | TACR1 (0.41) | NOS1NOS2NOS3TACR1RAPGEF4 | |
| SCHEMBL806193 | 0.81 | NOS1 (0.49) | NOS1NOS2NOS3TACR1TAAR1 | |
| SCHEMBL11564261 | 0.80 | TAAR1 (0.50) | NOS1NOS2NOS3TAAR1HRH3 | |
| SCHEMBL13983514 | 0.79 | NOS1 (0.43) | NOS1NOS2NOS3TAAR1RAPGEF4 | |
| Hydrochloric Acid SCHEMBL787716 | 0.79 | NOS1 (0.50) | NOS1NOS2NOS3TACR1TAAR1 | |
| SCHEMBL14570493 | 0.78 | IDO1 (0.43) | NOS1NOS2NOS3TACR1TAAR1 | |
| SCHEMBL16515444 | 0.78 | TAAR1 (0.55) | NOS1NOS2NOS3TAAR1RAPGEF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165440-A1 | JAK1 Inhibitors | EXELIXIS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| WO-2012037132-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165440-A1 | JAK1 Inhibitors | JAK1, JAK2, JAK3 | NOS1 1852/4885NOS2 2443/4885NOS3 3097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.